Compare Matson Inc (MATX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Neurocrine Biosciences Inc — how do they compare? Matson Inc trades at $218.3 (market cap $6.61B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× Matson Inc's market cap, and Matson Inc pays a 0.7% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MATX | NBIX | |
|---|---|---|
Market Cap | $6.61B | $17.40B |
Sector | Technology | Health |
52-Week High | $223.55 | $180.55 |
52-Week Low | $88.05 | $123.10 |
Enterprise Value | $7.21B | $16.49B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $218.41, down 1.7% today but maintains strong technical momentum with bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.85 exceeding expectations. Recent dividend increases and share repurchases highlight management's confidence, while preliminary Q2 2026 results project continued strength in Pacific shipping operations.
The outlook remains positive with analyst consensus favoring buys (64%) and technical indicators supporting upward momentum. Key risks include exposure to Pacific trade volatility and shipping rate fluctuations, but Matson's niche positioning and operational efficiency provide competitive advantages for sustained growth.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
